查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1980774

2026-2034年全球特发性肺纤维化治疗市场规模、份额、趋势和成长分析报告

Global Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 236 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2034 年，特发性肺纤维化治疗市场规模将从 2025 年的 39.6 亿美元增长至 89.8 亿美元，并预计从 2026 年到 2034 年将以 9.51% 的复合年增长率增长。

随着全球对罕见呼吸系统疾病的认识和诊断水准不断提高，特发性肺纤维化（IPF）治疗的全球市场持续扩大。特发性肺纤维化（IPF）是进行性性肺部疾病，其特征是肺组织瘢痕形成，逐渐损害呼吸功能。呼吸系统疾病盛行率的上升和诊断能力的提高，促使人们对有效的治疗方案的需求日益增长。

药物研发的进步正推动着能够延缓疾病进展、改善病患生活品质的药物的开发。医疗机构越来越重视早期诊断和疾病管理，以减轻与特发性肺纤维化（IPF）相关的併发症。此外，不断上涨的医疗成本和呼吸医学领域日益增长的研究活动也促进了该市场的成长。

未来几年，由于临床试验的持续进行和新治疗方法的研发，全球特发性肺纤维化（IPF）治疗市场预计将持续成长。製药公司正积极推动联合治疗和创新药物製剂的研究，旨在改善治疗效果。随着公众意识的提高和医疗服务可近性的改善，IPF治疗市场预计将保持稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球特发性肺纤维化治疗市场：依药物类别划分

  • 市场分析、洞察与预测
  • 酪胺酸抑制剂
  • MAPK抑制剂
  • 自泌素抑制剂
  • 其他的

第五章 全球特发性肺纤维化治疗市场：依药物市场划分

  • 市场分析、洞察与预测
  • Ofev
  • 埃斯布里特
  • Pirfenidone
  • 活动月
  • 任天堂
  • 干扰素-γ-1b
  • 其他的

第六章 全球特发性肺纤维化治疗市场：依药物类型划分

  • 市场分析、洞察与预测
  • 学名药
  • 品牌药品

第七章 全球特发性肺纤维化治疗市场：依类型划分

  • 市场分析、洞察与预测
  • OTC
  • 处方笺

第八章 全球特发性肺纤维化治疗市场：依给药途径划分

  • 市场分析、洞察与预测
  • 口服
  • 注射药物

第九章 全球特发性肺纤维化治疗市场：依最终用户划分

  • 市场分析、洞察与预测
  • 家庭医疗保健
  • 医院
  • 诊所
  • 其他的

第十章 全球特发性肺纤维化治疗市场：依通路划分

  • 市场分析、洞察与预测
  • 医院药房
  • 零售药房
  • 网路药房

第十一章 全球特发性肺纤维化治疗市场：按地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第十二章 竞争格局

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十三章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Boehringer Ingelheim International GmbH
    • GNI Group Ltd
    • MediciNova Inc
    • Cipla Inc
    • Bristol-Myers Squibb Company
    • Galapagos NV（Belgium）
    • United Therapeutics Corporation
    • FibroGen Inc
    • Veracyte Inc
简介目录
Product Code: VMR112115350

The Idiopathic Pulmonary Fibrosis Treatment Market size is expected to reach USD 8.98 Billion in 2034 from USD 3.96 Billion (2025) growing at a CAGR of 9.51% during 2026-2034.

The Global Idiopathic Pulmonary Fibrosis Treatment Market is expanding as awareness and diagnosis of rare respiratory diseases continue to improve worldwide. Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by scarring of lung tissue, which gradually impairs breathing. The increasing prevalence of respiratory disorders and improved diagnostic capabilities are contributing to the growing demand for effective treatment solutions.

Advancements in pharmaceutical research have led to the development of drugs that slow the progression of the disease and improve patient quality of life. Healthcare providers are increasingly focusing on early diagnosis and disease management to reduce complications associated with IPF. Additionally, rising healthcare expenditures and growing research initiatives in respiratory medicine are supporting the expansion of this market.

In the coming years, the Global Idiopathic Pulmonary Fibrosis Treatment Market is expected to grow due to ongoing clinical trials and the development of novel therapeutic approaches. Pharmaceutical companies are exploring combination therapies and innovative drug formulations aimed at improving treatment outcomes. With increasing awareness and improved healthcare access, the market for IPF treatments is projected to witness steady growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

  • Tyrosine Inhibitors
  • MAPK Inhibitors
  • Autotaxin Inhibitors
  • Others

By Marketed Drug

  • Ofev
  • Esbriet
  • Pirfenidone
  • Actimmune
  • Nintedanib
  • Interferon Gamma-1b
  • Others

By Medication Type

  • Generics
  • Branded

By Type

  • OTC
  • Prescription

By Route of Administration

  • Oral
  • Injectable

By End User

  • Home Healthcare
  • Hospitals
  • Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

COMPANIES PROFILED

  • F HoffmannLa Roche Ltd, Boehringer Ingelheim International GmbH, GNI Group Ltd, MediciNova Inc, Cipla Inc, BristolMyers Squibb Company, Galapagos NV Belgium, United Therapeutics Corporation, FibroGen Inc, Veracyte Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Tyrosine Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. MAPK Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Autotaxin Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY MARKETED DRUG 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Marketed Drug
  • 5.2. Ofev Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Esbriet Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Pirfenidone Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Actimmune Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Nintedanib Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Interferon Gamma-1b Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY MEDICATION TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Medication Type
  • 6.2. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Type
  • 7.2. OTC Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Prescription Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Route Of Administration
  • 8.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

  • 9.1. Market Analysis, Insights and Forecast End User
  • 9.2. Home Healthcare Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 10.1. Market Analysis, Insights and Forecast Distribution Channel
  • 10.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 11.1. Regional Outlook
  • 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.2.1 By Drug Class
    • 11.2.2 By Marketed Drug
    • 11.2.3 By Medication Type
    • 11.2.4 By Type
    • 11.2.5 By Route Of Administration
    • 11.2.6 By End User
    • 11.2.7 By Distribution Channel
    • 11.2.8 United States
    • 11.2.9 Canada
    • 11.2.10 Mexico
  • 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.3.1 By Drug Class
    • 11.3.2 By Marketed Drug
    • 11.3.3 By Medication Type
    • 11.3.4 By Type
    • 11.3.5 By Route Of Administration
    • 11.3.6 By End User
    • 11.3.7 By Distribution Channel
    • 11.3.8 United Kingdom
    • 11.3.9 France
    • 11.3.10 Germany
    • 11.3.11 Italy
    • 11.3.12 Russia
    • 11.3.13 Rest Of Europe
  • 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.4.1 By Drug Class
    • 11.4.2 By Marketed Drug
    • 11.4.3 By Medication Type
    • 11.4.4 By Type
    • 11.4.5 By Route Of Administration
    • 11.4.6 By End User
    • 11.4.7 By Distribution Channel
    • 11.4.8 India
    • 11.4.9 Japan
    • 11.4.10 South Korea
    • 11.4.11 Australia
    • 11.4.12 South East Asia
    • 11.4.13 Rest Of Asia Pacific
  • 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.5.1 By Drug Class
    • 11.5.2 By Marketed Drug
    • 11.5.3 By Medication Type
    • 11.5.4 By Type
    • 11.5.5 By Route Of Administration
    • 11.5.6 By End User
    • 11.5.7 By Distribution Channel
    • 11.5.8 Brazil
    • 11.5.9 Argentina
    • 11.5.10 Peru
    • 11.5.11 Chile
    • 11.5.12 South East Asia
    • 11.5.13 Rest of Latin America
  • 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.6.1 By Drug Class
    • 11.6.2 By Marketed Drug
    • 11.6.3 By Medication Type
    • 11.6.4 By Type
    • 11.6.5 By Route Of Administration
    • 11.6.6 By End User
    • 11.6.7 By Distribution Channel
    • 11.6.8 Saudi Arabia
    • 11.6.9 UAE
    • 11.6.10 Israel
    • 11.6.11 South Africa
    • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

  • 12.1. Recent Developments
  • 12.2. Company Categorization
  • 12.3. Supply Chain & Channel Partners (based on availability)
  • 12.4. Market Share & Positioning Analysis (based on availability)
  • 12.5. Vendor Landscape (based on availability)
  • 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT INDUSTRY

  • 13.1. Top Companies Market Share Analysis
  • 13.2. Company Profiles
    • 13.2.1 F. Hoffmann-La Roche Ltd
    • 13.2.2 Boehringer Ingelheim International GmbH
    • 13.2.3 GNI Group Ltd
    • 13.2.4 MediciNova Inc
    • 13.2.5 Cipla Inc
    • 13.2.6 Bristol-Myers Squibb Company
    • 13.2.7 Galapagos NV (Belgium)
    • 13.2.8 United Therapeutics Corporation
    • 13.2.9 FibroGen Inc
    • 13.2.10 Veracyte Inc